Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 5
2001 16
2002 28
2003 82
2004 126
2005 242
2006 318
2007 404
2008 485
2009 568
2010 640
2011 674
2012 796
2013 798
2014 806
2015 813
2016 780
2017 754
2018 716
2019 745
2020 781
2021 161
Text availability
Article attribute
Article type
Publication date

Search Results

9,435 results
Results by year
Filters applied: . Clear all
Page 1
Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib.
Tan CRC, Abdul-Majeed S, Cael B, Barta SK. Tan CRC, et al. Clin Pharmacokinet. 2019 Feb;58(2):157-168. doi: 10.1007/s40262-018-0679-9. Clin Pharmacokinet. 2019. PMID: 29802543 Review.
Bortezomib is available for subcutaneous and intravenous administration. ...In addition, we discuss the clinical efficacy and safety of bortezomib....
Bortezomib is available for subcutaneous and intravenous administration. ...In addition, we discuss the clinical efficacy and safety
The safety of bortezomib for the treatment of multiple myeloma.
Cengiz Seval G, Beksac M. Cengiz Seval G, et al. Expert Opin Drug Saf. 2018 Sep;17(9):953-962. doi: 10.1080/14740338.2018.1513487. Epub 2018 Aug 30. Expert Opin Drug Saf. 2018. PMID: 30118610 Review.
Bortezomib can be administered in the outpatient setting with manageable toxicities. ...This review gives an overview of the critical role of the bortezomib in multiple myeloma and provides a comprehensive summary of key clinical benefit and safety data with the
Bortezomib can be administered in the outpatient setting with manageable toxicities. ...This review gives an overview of the critical
Bortezomib for the treatment of multiple myeloma.
Scott K, Hayden PJ, Will A, Wheatley K, Coyne I. Scott K, et al. Cochrane Database Syst Rev. 2016 Apr 20;4:CD010816. doi: 10.1002/14651858.CD010816.pub2. Cochrane Database Syst Rev. 2016. PMID: 27096326 Review.
SELECTION CRITERIA: We included randomised controlled trials (RCTs) that compared i) bortezomib versus no bortezomib with the same background therapy in each arm; ii) bortezomib versus no bortezomib with different background therapy in each arm or comp …
SELECTION CRITERIA: We included randomised controlled trials (RCTs) that compared i) bortezomib versus no bortezomib with the …
Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later.
Robak P, Robak T. Robak P, et al. Drugs R D. 2019 Jun;19(2):73-92. doi: 10.1007/s40268-019-0269-9. Drugs R D. 2019. PMID: 30993606 Free PMC article. Review.
Bortezomib is a dipeptidyl boronic acid that selectively inhibits the ubiquitin proteasome pathway, which plays a role in the degradation of many intracellular proteins. ...In 2006, bortezomib was approved for the treatment of refractory/relapsed mantle cell lymphom
Bortezomib is a dipeptidyl boronic acid that selectively inhibits the ubiquitin proteasome pathway, which plays a role in the degrada
Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis.
Zhang S, Kulkarni AA, Xu B, Chu H, Kourelis T, Go RS, Wang ML, Bachanova V, Wang Y. Zhang S, et al. Blood Cancer J. 2020 Mar 6;10(3):33. doi: 10.1038/s41408-020-0298-1. Blood Cancer J. 2020. PMID: 32144237 Free PMC article.
Bortezomib-based regimens are widely used as induction therapy for multiple myeloma (MM). ...Ten RCTs enrolling 3147 patients were included in the meta-analysis. Bortezomib-based regimens were compared with regimens without bortezomib or observation. ...
Bortezomib-based regimens are widely used as induction therapy for multiple myeloma (MM). ...Ten RCTs enrolling 3147 patients were in
Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment.
Velasco R, Alberti P, Bruna J, Psimaras D, Argyriou AA. Velasco R, et al. J Peripher Nerv Syst. 2019 Oct;24 Suppl 2:S52-S62. doi: 10.1111/jns.12338. J Peripher Nerv Syst. 2019. PMID: 31647153 Review.
Proteasome inhibitors (PIs), especially bortezomib (BTZ), have come to the forefront over the last years because of their unprecedented efficacy mainly against multiple myeloma (MM). Unfortunately, peripheral neuropathy (PN) secondary to treatment of MM with PIs has emerge …
Proteasome inhibitors (PIs), especially bortezomib (BTZ), have come to the forefront over the last years because of their unprecedent …
A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.
Eskandary F, Regele H, Baumann L, Bond G, Kozakowski N, Wahrmann M, Hidalgo LG, Haslacher H, Kaltenecker CC, Aretin MB, Oberbauer R, Posch M, Staudenherz A, Handisurya A, Reeve J, Halloran PF, Böhmig GA. Eskandary F, et al. J Am Soc Nephrol. 2018 Feb;29(2):591-605. doi: 10.1681/ASN.2017070818. Epub 2017 Dec 14. J Am Soc Nephrol. 2018. PMID: 29242250 Free PMC article. Clinical Trial.
Uncontrolled studies have suggested efficacy of the proteasome inhibitor bortezomib, but no systematic trial has been undertaken to support its use in ABMR. ...Bortezomib, however, associated with gastrointestinal and hematologic toxicity. ...
Uncontrolled studies have suggested efficacy of the proteasome inhibitor bortezomib, but no systematic trial has been undertaken to s …
Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysis.
Sun CY, Li JY, Chu ZB, Zhang L, Chen L, Hu Y. Sun CY, et al. Biosci Rep. 2017 Jul 27;37(4):BSR20170304. doi: 10.1042/BSR20170304. Print 2017 Aug 31. Biosci Rep. 2017. PMID: 28706008 Free PMC article. Review.
Multiple myeloma (MM) is a B-cell neoplasm with a high incidence of relapse. Bortezomib has been extensively studied for the maintenance treatment of MM. ...Additionally, more RCTs are needed for better understanding and determination of optimal bortezomib maintenan …
Multiple myeloma (MM) is a B-cell neoplasm with a high incidence of relapse. Bortezomib has been extensively studied for the maintena …
Acupuncture for Bortezomib-Induced Peripheral Neuropathy: Not Just for Pain.
Zhi WI, Ingram E, Li SQ, Chen P, Piulson L, Bao T. Zhi WI, et al. Integr Cancer Ther. 2018 Dec;17(4):1079-1086. doi: 10.1177/1534735418788667. Epub 2018 Jul 20. Integr Cancer Ther. 2018. PMID: 30027756 Free PMC article. Clinical Trial.
BACKGROUND: Bortezomib-induced peripheral neuropathy (BIPN) is a common and debilitating side effect. ...PURPOSE: To characterize individual symptoms reduced by acupuncture in patients with BIPN. METHODS: Patients with multiple myeloma treated with bortezomib who de …
BACKGROUND: Bortezomib-induced peripheral neuropathy (BIPN) is a common and debilitating side effect. ...PURPOSE: To characterize ind …
Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group.
Horton TM, Whitlock JA, Lu X, O'Brien MM, Borowitz MJ, Devidas M, Raetz EA, Brown PA, Carroll WL, Hunger SP. Horton TM, et al. Br J Haematol. 2019 Jul;186(2):274-285. doi: 10.1111/bjh.15919. Epub 2019 Apr 7. Br J Haematol. 2019. PMID: 30957229 Free PMC article. Clinical Trial.
Previous studies suggest proteasome inhibition with chemotherapy improves relapse ALL response rates. This phase 2 Children's Oncology Group study tested the hypothesis that adding the proteasome inhibitor bortezomib to chemotherapy increases complete response rates …
Previous studies suggest proteasome inhibition with chemotherapy improves relapse ALL response rates. This phase 2 Children's Oncolog …
9,435 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page